Northfield Laboratories Inc., bleeds

Northfield released its financial results for the fourth fiscal quarter and year-ended May 31, 2007, informing shareholders that it lost 24 cents a share in the 4th quarter and $1.03 for fiscal 2007. Plans are in place for 2008 . . .

"Our singular focus in FY08 is the successful submission of a Biologics License Application for PolyHeme® with a request for priority review," said Steven A. Gould, M.D., Chairman and Chief Executive Officer. "We have already submitted a detailed summary of the pivotal Phase III trial data to FDA, which was followed by a pre-BLA meeting. Given our strong belief in PolyHeme's ability to address a critical unmet medical need and its potential to save lives, we are committed to making our product available for patients with urgent, life-threatening blood loss when blood is not available."

Northfield's press release included summary coverage of topics listed below (and others):

Highlights of the Year and Upcoming Events
Commercialization Activities
Financial
Investor Outreach
Annual Meeting of Stockholders

I am looking forward to the day when Rambus Inc. provides its shareholders with a date for its annual meeting and shares similar information . . .